- cafead Sep 18, 2022 at 10:42: PM
via Intellia Therapeutics reported early, positive signs from its in vivo gene therapies for both transthyretin (ATTR) amyloidosis and hereditary angioedema Friday.
The data released from the two early-stage programs represent a major milestone for each disease space and validate the company’s in-vivo-based CRISPR platform, John Leonard, Intellia’s chief executive, said in a conference call.
article source
The data released from the two early-stage programs represent a major milestone for each disease space and validate the company’s in-vivo-based CRISPR platform, John Leonard, Intellia’s chief executive, said in a conference call.
article source